News

Puma Biotechnology announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. that grants Knight the exclusive right to commercialize NERLYNX…
Read More...

SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has promoted Michael D. Scholle to chief operating officer. Formerly serving as director and…
Read More...

SIRION Biotech GmbH announced that it signed a license and collaboration agreement with Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product…
Read More...

Clinigen Group plc announces that its Clinical Trial Service business has extended its exclusive European clinical trial supply agreement with Accord Healthcare. Clinigen is also…
Read More...

Selexis SA announced that it has signed additional commercial license agreements (CLAs) with Agenus, an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer…
Read More...

Takeda Pharmaceutical Company Limited announced the completion of its acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in…
Read More...

AbSci announced a collaboration with Sanofi.  Under the terms of the agreement, AbSci will apply its breakthrough E.coli manufacturing platform, SoluProTM, and its novel optimization…
Read More...

Pharmaceutics International announced its partner, Academic Pharmaceuticals, Inc., received FDA approval of Bretylium Tosylate Injection USP, 500 mg/10 mL (50 mg/mL) Single-Dose Vials…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs)…
Read More...

Almac Sciences, a member of the Almac Group, has expanded its technology capabilities within its Active Pharmaceutical Ingredients (API) services & chemical development portfolio…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases announced its plans to initiate a…
Read More...

Aphena Pharma Solutions Inc. has announced the expansion of its blister packaging capacity with the purchase of a PharmaWorks TF2 blister packaging line with in-line cartoning…
Read More...

Ascentage Pharma announced that Unity Biotechnology has selected one of Ascentage's compounds as its lead development candidate in its ophthalmology pipeline to advance into further…
Read More...

Generex Biotechnology Corporation announced that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc., a New York based regenerative medicine company that is…
Read More...

CANbridge Pharmaceuticals and WuXi Biologics jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional…
Read More...

Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, announced that it has entered into a collaboration agreement with BioMed X Innovation…
Read More...

Regeneron Pharmaceuticals and Sanofi have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval…
Read More...

CytoReason announced that it has entered into a collaboration agreement with Pfizer that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive…
Read More...

GE Healthcare and Vanderbilt University Medical Center (VUMC) announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will…
Read More...